Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01771809 · ClinicalTrials.gov registry record · Phase 2
Long-Term Safety Of PF-00547659 In Ulcerative Colitis
A Phase 2 study, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 330
- Enrollment target
NCT01771809 is a Phase 2 study that has completed, run by Shire. The registered enrollment target is 330 participants.
The verdict
NCT01771809, a Phase 2 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 330 participants
- Enrollment target
Study Summary
Subjects with Ulcerative Colitis who have completed an induction study with PF-00547659 will receive an additional 144 weeks of open-label treatment to evaluate the long-term safety of the drug.
Interventions
- DRUG 75mg SHP647 (PF-00547659)
- DRUG 225mg SHP647 (PF-00547659)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2013-03-18 |
| Est. Completion | 2017-12-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01771809
The ClinicalTrials.gov registry entry for NCT01771809 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 75mg SHP647 (PF-00547659) is the first listed.
NCT01771809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01771809 about?
NCT01771809 is a clinical study titled "Long-Term Safety Of PF-00547659 In Ulcerative Colitis". Subjects with Ulcerative Colitis who have completed an induction study with PF-00547659 will receive an additional 144 weeks of open-label treatment to evaluate the long-term safety of the drug.
What is the current status of trial NCT01771809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 330 participants. The study started on 2013-03-18. Estimated completion is 2017-12-13.
What interventions are being tested in trial NCT01771809?
The interventions under investigation include: 75mg SHP647 (PF-00547659) (DRUG), 225mg SHP647 (PF-00547659) (DRUG).
Who is sponsoring clinical trial NCT01771809?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.